I had the same problem. Even Polymedixs did not make their pharmacokinetics report where the measures were easily transferable to make the needed calculations. The final RBL report should be available in a few weeks; hopefully, we can make better comparisons then, especially to Remdesivir.
Our only substantial antiviral competitor is Remdesivir which has the highest SI for Covid 19 to date. The SI is simply a ratio of the toxic dose to the effective dose. Remdesivir has more reported side effects than Brilacidin and seems to be less potent. If that proves true it is very possible Brilacin's SI will be higher than Remdesivir.